drugset / Trial / NCT06504030
Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis
NaSingle-groupOpen-labelTreatment
Summary
This study is trying to evaluate the efficacy and safety of modified DEP regimens for the treatment of active hemophagocytic lymphohistiocytosis.
Timeline
- Start
- 2024-08-01
- Primary completion
- 2026-08-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | — |
| Subject | Etoposide | Small molecule | 100 mg/m2 | — |
| Subject | Methylprednisolone | Other / unclassified | 1 mg/kg | — |
| Subject | Ruxolitinib | Small molecule | 15 mg | — |
| Background | Emapalumab | Monoclonal antibody | — | — |